{"id":"https://openalex.org/W7203702655","doi":"https://doi.org/10.1080/10428194.2026.2714343","title":"Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia","display_name":"Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia","publication_year":2026,"publication_date":"2026-08-18","ids":{"openalex":"https://openalex.org/W7203702655","doi":"https://doi.org/10.1080/10428194.2026.2714343","pmid":"https://pubmed.ncbi.nlm.nih.gov/42611806"},"language":"en","primary_location":{"id":"doi:10.1080/10428194.2026.2714343","doi":"https://doi.org/10.1080/10428194.2026.2714343","is_oa":true,"landing_page_url":"https://doi.org/10.1080/10428194.2026.2714343","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/10428194.2026.2714343?needAccess=true","source":{"id":"https://openalex.org/S27064115","display_name":"Leukemia & lymphoma/Leukemia and lymphoma","issn_l":"1026-8022","issn":["1026-8022","1029-2403","1042-8194"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Leukemia & Lymphoma","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://www.tandfonline.com/doi/pdf/10.1080/10428194.2026.2714343?needAccess=true","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082924494","display_name":"Daniel J. DeAngelo","orcid":"https://orcid.org/0000-0001-7865-2306","observed_orcids":["https://orcid.org/0000-0001-7865-2306"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel J. DeAngelo","raw_affiliation_strings":["Department of Medical Oncology, Dana\u2013Farber Cancer Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana\u2013Farber Cancer Institute","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100383140","display_name":"Ying Chen","orcid":"https://orcid.org/0009-0005-8351-6620","observed_orcids":["https://orcid.org/0009-0005-8351-6620"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ying Chen","raw_affiliation_strings":["Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071844603","display_name":"Ryan Daniel Cassaday","orcid":"https://orcid.org/0000-0002-3424-2425","observed_orcids":["https://orcid.org/0000-0002-3424-2425"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan D. Cassaday","raw_affiliation_strings":["University of Washington and Fred Hutchinson Cancer Center"],"raw_orcid":"https://orcid.org/0000-0002-3424-2425","affiliations":[{"raw_affiliation_string":"University of Washington and Fred Hutchinson Cancer Center","institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069542012","display_name":"Jennifer E. Hibma","orcid":"https://orcid.org/0000-0002-6547-2186","observed_orcids":["https://orcid.org/0000-0002-6547-2186"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer E. Hibma","raw_affiliation_strings":["Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074854506","display_name":"Derek Z. Yang","orcid":"https://orcid.org/0000-0002-3642-7757","observed_orcids":["https://orcid.org/0000-0002-3642-7757"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Derek Z. Yang","raw_affiliation_strings":["Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081271382","display_name":"May Garrett","orcid":"https://orcid.org/0000-0002-8090-2842","observed_orcids":["https://orcid.org/0000-0002-8090-2842"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"May Garrett","raw_affiliation_strings":["Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100403434","display_name":"Fan Zhang","orcid":"https://orcid.org/0000-0002-0942-7305","observed_orcids":["https://orcid.org/0000-0002-0942-7305"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fan Zhang","raw_affiliation_strings":["Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079716588","display_name":"Svetoslav Dimitrov","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Svetoslav H. Dimitrov","raw_affiliation_strings":["Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009581524","display_name":"Erik R. Vandendries","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erik R. Vandendries","raw_affiliation_strings":["Pfizer Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5090435894","display_name":"Hagop M. Kantarjian","orcid":"https://orcid.org/0000-0002-1908-3307","observed_orcids":["https://orcid.org/0000-0002-1908-3307"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Hagop M. Kantarjian","raw_affiliation_strings":["Leukemia Department, The University of Texas MD Anderson Cancer Center"],"raw_orcid":"https://orcid.org/0000-0002-1908-3307","affiliations":[{"raw_affiliation_string":"Leukemia Department, The University of Texas MD Anderson Cancer Center","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5090435894"],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.48627145,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"67","issue":"11","first_page":"2206","last_page":"2216"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0034000000450760126,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/inotuzumab-ozogamicin","display_name":"inotuzumab ozogamicin","score":1.0},{"id":"https://openalex.org/keywords/dose-optimization","display_name":"dose optimization","score":0.8050000071525574},{"id":"https://openalex.org/keywords/relapsed-refractory-acute-lymphoblastic-leukemia","display_name":"relapsed/refractory acute lymphoblastic leukemia","score":0.9639999866485596},{"id":"https://openalex.org/keywords/dose-fractionation","display_name":"dose fractionation","score":0.7730000019073486},{"id":"https://openalex.org/keywords/exposure-response-analysis","display_name":"exposure-response analysis","score":0.8930000066757202},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.5109999775886536},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.46799999475479126},{"id":"https://openalex.org/keywords/drug-efficacy-and-safety","display_name":"drug safety and efficacy","score":0.7260000109672546}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8596000075340271},{"id":"https://openalex.org/C2909962599","wikidata":"https://www.wikidata.org/wiki/Q180664","display_name":"Lymphoblastic Leukemia","level":3,"score":0.6165000200271606},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5784000158309937},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5690000057220459},{"id":"https://openalex.org/C2781107101","wikidata":"https://www.wikidata.org/wiki/Q180664","display_name":"Acute lymphocytic leukemia","level":4,"score":0.424699991941452},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3066999912261963},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.2847000062465668},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.2720000147819519},{"id":"https://openalex.org/C2993769353","wikidata":"https://www.wikidata.org/wiki/Q7598360","display_name":"Standard of care","level":2,"score":0.2696000039577484},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2671000063419342},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.2662999927997589},{"id":"https://openalex.org/C2778623314","wikidata":"https://www.wikidata.org/wiki/Q412685","display_name":"Gemtuzumab ozogamicin","level":5,"score":0.2590999901294708}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000080045","descriptor_name":"Inotuzumab Ozogamicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000080045","descriptor_name":"Inotuzumab Ozogamicin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000080045","descriptor_name":"Inotuzumab Ozogamicin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D054198","descriptor_name":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D054198","descriptor_name":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D054198","descriptor_name":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1080/10428194.2026.2714343","doi":"https://doi.org/10.1080/10428194.2026.2714343","is_oa":true,"landing_page_url":"https://doi.org/10.1080/10428194.2026.2714343","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/10428194.2026.2714343?needAccess=true","source":{"id":"https://openalex.org/S27064115","display_name":"Leukemia & lymphoma/Leukemia and lymphoma","issn_l":"1026-8022","issn":["1026-8022","1029-2403","1042-8194"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Leukemia & Lymphoma","raw_type":"journal-article"},{"id":"pmid:42611806","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42611806","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Leukemia & lymphoma","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1080/10428194.2026.2714343","doi":"https://doi.org/10.1080/10428194.2026.2714343","is_oa":true,"landing_page_url":"https://doi.org/10.1080/10428194.2026.2714343","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/10428194.2026.2714343?needAccess=true","source":{"id":"https://openalex.org/S27064115","display_name":"Leukemia & lymphoma/Leukemia and lymphoma","issn_l":"1026-8022","issn":["1026-8022","1029-2403","1042-8194"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Leukemia & Lymphoma","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9763000011444092,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7203702655.pdf","grobid_xml":"https://content.openalex.org/works/W7203702655.grobid-xml"},"referenced_works_count":28,"referenced_works":["https://openalex.org/W1488000644","https://openalex.org/W1985380961","https://openalex.org/W2066508515","https://openalex.org/W2126855868","https://openalex.org/W2419639370","https://openalex.org/W2725721905","https://openalex.org/W2922526548","https://openalex.org/W2931981435","https://openalex.org/W2942381021","https://openalex.org/W2944605276","https://openalex.org/W3053993225","https://openalex.org/W3159031217","https://openalex.org/W4295517297","https://openalex.org/W4307155775","https://openalex.org/W4367834551","https://openalex.org/W4381149229","https://openalex.org/W4386252474","https://openalex.org/W4387966287","https://openalex.org/W4396834704","https://openalex.org/W4396976305","https://openalex.org/W4401253431","https://openalex.org/W4403508383","https://openalex.org/W4405041165","https://openalex.org/W4405044303","https://openalex.org/W4407000529","https://openalex.org/W4407908356","https://openalex.org/W7162678860","https://openalex.org/W7166298721"],"related_works":["https://openalex.org/W4405042779","https://openalex.org/W3213020069","https://openalex.org/W3093461422","https://openalex.org/W4405042684","https://openalex.org/W2971026936","https://openalex.org/W4248843398","https://openalex.org/W4407000529","https://openalex.org/W4396834704","https://openalex.org/W3053993225","https://openalex.org/W4224920792"],"abstract_inverted_index":{"Following":[0],"the":[1,9,19,35,47,64,76],"approval":[2],"of":[3,11,38,51,58],"inotuzumab":[4],"ozogamicin":[5],"(InO)":[6],"monotherapy":[7],"for":[8,66,75],"treatment":[10],"adults":[12],"with":[13],"relapsed/refractory":[14],"CD22-positive":[15],"acute":[16],"lymphoblastic":[17],"leukemia,":[18],"US":[20],"Food":[21],"and":[22,49,73,84],"Drug":[23],"Administration":[24],"issued":[25],"a":[26,68],"post-marketing":[27],"requirement":[28],"study":[29],"due":[30],"to":[31],"their":[32],"concerns":[33],"that":[34],"proposed":[36],"dose":[37],"1.8":[39],"mg/m2/cycle":[40],"may":[41],"not":[42],"be":[43],"optimal":[44],"in":[45],"balancing":[46],"safety":[48,83],"efficacy":[50,85],"InO.":[52],"Here,":[53],"we":[54],"provide":[55],"an":[56],"overview":[57],"single-agent":[59],"InO":[60,70,94],"dose-optimization":[61],"strategies,":[62],"including":[63],"rationale":[65],"studying":[67],"fractionated":[69],"dosing":[71,78],"schedule":[72],"justification":[74],"approved":[77],"regimen":[79],"based":[80],"on":[81],"clinical":[82,95],"data,":[86],"as":[87,89],"well":[88],"comprehensive":[90],"exposure\u2013response":[91],"analyses":[92],"from":[93],"studies.":[96]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2026-08-19T00:00:00"}